Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Adenovirus Type 5 Injection for High-Risk Non-Muscle Invasive Bladder Cancer
NCT07356791Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
01
Overview
A Phase 2 trial of Oncorine in non-muscle-invasive bladder cancer (NMIBC), sponsored by Renji Hospital. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
Oncorine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07356791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07356791.